Overview

Phase I Study Compound 451238 and Radiotherapy in Soft-tissue Sarcoma

Status:
Recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
The objective of this trial is to assess the safety and tolerability of combining compound 451238 and radiotherapy, treating advanced STS.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Royal Marsden NHS Foundation Trust
Collaborators:
Merck KGaA
Merck KGaA, Darmstadt, Germany